Glycosylation is a critical post-translational modification that affects the stability, activity, and immunogenicity of therapeutic proteins. P. pastoris is a well-characterized yeast expression system that can produce high levels of recombinant proteins with human-like glycosylation patterns. Glycoengineering of P. pastoris involves modifying the yeast's glycosylation pathways to produce recombinant proteins with specific glycan structures that match those found in humans. The resulting glycoengineered P. pastoris strains can produce recombinant proteins with improved efficacy, stability, and safety profiles.
CD Biosynsis is a company that specializes in providing services for glycoengineering of P. pastoris to optimize the production of recombinant proteins with desired glycan structures.
Figure 1: Graphical abstract of the application of synthetic biology for biopharmaceutical production in Pichia pastoris. (Vogl T., et al. 2013)
Our strain development services involve modifying the glycosylation pathways of P. pastoris to produce recombinant proteins with specific glycan structures that match those found in humans. We use a range of genetic engineering techniques, such as site-directed mutagenesis, gene knockouts, and gene overexpression, to engineer the glycosylation pathways of P. pastoris. We can also perform codon optimization to enhance the expression of the recombinant protein. Our glycoengineered P. pastoris strains can produce recombinant proteins with homogenous glycan structures, which is critical for maintaining the protein's efficacy and safety profiles.
We optimize the metabolic pathways of glycoengineered P. pastoris strains for improved recombinant protein production. We use genome-scale metabolic models, flux balance analysis, and omics data analysis to identify metabolic bottlenecks and optimize the metabolic pathways. We can also modify the carbon source and nutrient availability to enhance the production of the target protein. Our metabolic engineering strategies can significantly increase the yield and quality of recombinant proteins produced in glycoengineered P. pastoris strains.
We use bioreactor systems to monitor and control the cultivation parameters, such as dissolved oxygen, pH, and temperature. We also use mixed feeding strategies, such as fed-batch and continuous feeding, to optimize the nutrient supply and maximize the production of the target protein. We can also use biocalorimetry to monitor the metabolic activity of the cells and optimize the feeding strategy for higher protein production. Our bioprocess optimization strategies can significantly improve the yield and quality of recombinant proteins produced in glycoengineered P. pastoris strains.
We offer customized services tailored to the specific needs of our clients.
Our services can help clients to accelerate their drug development pipeline and bring their products to market faster.
Glycoengineering of P. pastoris is an important strategy for the production of recombinant proteins with human-like glycosylation patterns. CD Biosynsis offers a range of services for glycoengineering of P. pastoris to optimize the production of recombinant proteins with desired glycan structures. Our expertise, customization, and quality make us a trusted partner for clients in the biopharmaceutical and industrial sectors. Contact us today to learn more about our services for glycoengineering of Pichia pastoris.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.